⚠ BETA β€” all market data shown (deals, filings, prices, indices) is demo / illustrative, not live trading data. For evaluation only; verify before acting.
June 17, 2026

NSE

Biocon LimitedBIOCON

BIOCONβ‚Ή411.85β–Ό 0.99% today
Nifty Midcap 150

Biocon is a biopharmaceuticals company strong in biosimilars.

Key productsBiosimilars (via Biocon Biologics), generics, APIs and research services (Syngene).
GeographyGlobal.
CompetitorsDr Reddy's, global biosimilar makers.

AI-generated overview β€” verify before relying on it.

Net institutional flow

No institutional deals

Institutional buyers

0 in / 0 out

High-impact filings

0 Β· tilt Neutral

Next corporate action

Dividend - Re 0.50 Per Share

ex 2026-07-03

Competitive landscape β€” the read

vs mapped peers Β· 1Y
Institutional money is backing APOLLOHOSP hardest (+β‚Ή1,108.9 Cr net). BIOCON ranks #2 of 9 on flow (net buying +β‚Ή0 Cr). Filing momentum favours ZYDUSLIFE (+1). News & social buzz is most positive on DRREDDY.
#CompanyInst. flow β‚ΉCrDealsHi-impactFiling mom.BuzzNews
1APOLLOHOSP+β‚Ή1,108.9 Cr491β€”β€”β€”
2BIOCONThisβ€”β€”β€”β€”β€”β€”
3CIPLA+β‚Ή0 Cr4β€”β€”+1944
4DRREDDY+β‚Ή0 Cr4β€”β€”+2046
5SUNPHARMA+β‚Ή0 Cr6β€”β€”+1545
6TORNTPHARMβ€”β€”β€”β€”β€”β€”
7LUPIN+β‚Ή0 Cr4β€”β€”β€”β€”
8ZYDUSLIFEβ€”β€”1+1β€”β€”
9AUROPHARMA+β‚Ή0 Cr2β€”β€”β€”β€”

Ranked by net institutional flow (buys βˆ’ sells, β‚ΉCr). Filing momentum = bullish βˆ’ bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.

SWOT

Strengths

  • β€’ [object Object]
  • β€’ [object Object]

Weaknesses

  • β€’ [object Object]
  • β€’ [object Object]

Opportunities

  • β€’ [object Object]
  • β€’ [object Object]

Threats

  • β€’ [object Object]
  • β€’ [object Object]

AI-generated from our data β€” verify before relying on it.

Timeline β€” BIOCON day by day

Merged from deals, filings, corporate actions and news β€” newest first. Compact rolls each day up to net flow + counts. Scope with the range above.

Filings that matter

  • 2
    Shareholding DisclosureNeutral

    a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

    Source PDF β†’
  • 2
    M&ANeutral

    Acquisition

    Source PDF β†’
  • 2
    MeetingNeutral

    voting results.

    Source PDF β†’
  • 2
    Investor CallNeutral

    Schedule of meet

    Source PDF β†’

Bulk & block deals

No bulk/block deals for BIOCON in this window.

Results & transcripts

News & chatter on BIOCON

RSS News

0

No recent news.

Google News RSS β€” links open the source.

Investdesk

0

No articles yet.

Our coverage.

Reddit

0

No Reddit chatter.

r/ posts mentioning the company.

Twitter / X

0

No posts.

Posts mentioning the company.